December 2, 2015
Flood in Chennai suspends operations at Natco Pharma API plant (India)
Flood in India’s Chennai suspends operations at Natco Pharma API plant
Pharmaceuticals, Biotechnology and Life Sciences
Author: Dino Mustafić
December 1, 2015
Savy Akers’ production facility in China fully operational
Savy Akers’ 10,000 square foot production facility in Haikou National Hi-Tech Industrial Zone, Hainan province, is now fully operational.
December 1, 2015
Horizon Pharma gets additional notice of allowance with claims covering Pennsaid 2%
Horizon Pharma has received a Notice of Allowance from the United States Patent and Trademark Office (USPTO) for U.S. patent application number entitled “Treatment of Pain with Topical Diclofenac” for a drug Pennsaid 2% w/w.
December 1, 2015
Number of AIDS deaths among young Asians doubles over past decade – U.N
The estimated number of adolescents dying of AIDS in the Asia Pacific region has more than doubled since 2005, experts said on Monday, warning of a “hidden epidemic”.
UNICEF urged Asian countries to improve teenagers’ access to testing, saying many young people do not know their HIV status because of parental consent requirements for tests.
December 1, 2015
AHF marks World AIDS Day with HIV testing & awareness events in 32 countries
AHF Marks World AIDS Day with HIV Testing & Awareness Events in 32 Countries; Celebrates Milestone: 500,000 Lives in Care
December 1, 2015
Celyad advances first NKG2D CAR T-Cell Phase I study
Celyad advances first NKG2D CAR T-Cell Phase I study
December 1, 2015
French Biophytis appoints new Director of Research
Biophytis has appointed Pierre J. Dilda, PhD, as Director of
Research.
December 1, 2015
Frances Neovacs engaging in immuno-oncology
Neovacs, a France-based specialist in active immunotherapies for the treatment of autoimmune diseases, has decided to engage in the field of immuno-oncology after a recommendations by its Scientific Adivsory Board
December 1, 2015
Tuberculosis funding gap threatens elimination goals
Funding for tuberculosis research fell $1.3 billion short of global targets last year, threatening worldwide goals to eliminate the disease between 2030 and 2035, researchers said on Monday.
December 1, 2015
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target
Velneva’s Clostridium difficile vaccine Candidate meets Phase II trial target